This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	TANK-binding kinase 1 (TBK1)	<p>Mouse studies suggest that inhibiting TBK1 could help treat cancer. In mice with pancreatic or breast cancer cells expressing anti-TBK1 small hairpin RNA, tumor growth and metastasis were impaired compared with those in cells expressing control shRNA. In TBK1-dependent non-small cell lung cancer (NSCLC) cell lines, a small molecule inhibitor of TBK1 was cytotoxic compared with vehicle control. Next steps could include additional animal studies of the TBK1 inhibitor.</p> <p>Coronado Biosciences Inc.'s TBK1 inhibitor, CNDO102, is in Phase I/II testing to treat cancer. Myrexix Inc.'s TBK1 inhibitor, MPI-0485520, is in preclinical testing to treat autoimmune diseases and cancer.</p> <p>SciBX 4(10); doi:10.1038/scibx.2011.279 Published online March 10, 2011</p>	Patent and licensing status unavailable	<p>Ou, Y.-H. <i>et al. Mol. Cell</i>; published online Feb. 18, 2011; doi:10.1016/j.molcel.2011.01.019 Contact: Michael A. White, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: michael.white@utsouthwestern.edu Contact: Seng-Lai Tan, Amgen Inc., Seattle, Wash. e-mail: sengt@amgen.com</p>